We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Summit Therapeutics Plc | LSE:SUMM | London | Ordinary Share | GB00BN40HZ01 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 20.50 | 18.00 | 23.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
By Anne Steele
Prices of International stocks trading in New York closed higher on Thursday.
The BNY Mellon index of American depositary receipts rose 0.4% to 140.07. The European index increased 0.3% to 133.16, the Asian index improved 0.3% to 159.79, the Latin American index climbed 1% to 212.84 and the emerging markets index increased 0.3% to 287.26.
Pharmaceutical companies were among those trading actively.
ADRs of Teva Pharmaceutical Industries Ltd. (TEVA.TV, TEVA) ended 4.7% higher at $32.52 after Mizuho raised its rating to neutral from underperform.
ADRs of Novartis AG (NVS, NOVN.EB) rose 4.6% to $86.34 after the company said a drug that it sells for various immunology conditions reduced the risk of serious heart problems in patients who have had a heart attack and who suffer inflammation related to fat build-up in the arteries.
ADRs of Summit Therapeutics PLC (SMMT, SUMM.LN) climbed 3.7% to $11.49 after the company presented data from two early-stage clinical trials of its Duchenne muscular dystrophy drug ezutromid.
Write to Anne Steele at anne.steele@wsj.com.
(END) Dow Jones Newswires
June 22, 2017 17:29 ET (21:29 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Summit Therapeutics Chart |
1 Month Summit Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
